July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Protecting the Mitochondria as a Therapeutic Strategy for dry Age-Related Macular Degeneration
Author Affiliations & Notes
  • Deborah A. Ferrington
    Ophthalmology & Visual Neuroscience, University of Minnesota, Shoreview, Minnesota, United States
  • Footnotes
    Commercial Relationships   Deborah Ferrington, None
  • Footnotes
    Support  NIH EY026012, Foundation Fighting Blindness, Minnesota Lions Vision Foundation, Beckman Inititative for Macular Research, Regenerative Medicine Minnesota, Anonymous Donor for AMD Research, Lindsay Family Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1609. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Deborah A. Ferrington; Protecting the Mitochondria as a Therapeutic Strategy for dry Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1609.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Previous results from proteomic and mtDNA damage analysis have suggested that defects in the retinal pigment epithelium (RPE) mitochondria occur at an early stage of AMD. Using primary cultures of RPE from donors with or without AMD, we found that mitochondrial function is decreased in cells from donors with AMD suggesting these RPE are in a bioenergetics crisis. As a potential therapeutic treatment, we have been testing drugs that protect or improve mitochondrial function. We found large variability in the response to different mitochondrial-targeted drugs between individual donors, suggesting a need for tailoring treatment to individual patients. To provide a platform for patient-specific treatment, we have made induced pluripotent stem cells (iPSC) from biopsies of the conjunctiva and then differentiated these cells into RPE. The iPSC-RPE is used to test a battery of drugs so that the optimal drug can be selected for each patient with AMD. This is a novel system that may enable patient-specific treatment for age-related macular degeneration.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.